 |
|
Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
Wonkyo Shin, Hye-joo Lee, Seong J. Yang, E sun Paik, Hyun-jin Choi, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Byoung-Gie Kim
Obstet Gynecol Sci. 2018;61(3):352-358. Published online 2018 May 9 DOI: https://doi.org/10.5468/ogs.2018.61.3.352
|
|
Citations to this article as recorded by
 Ifosfamide-induced nephrotoxicity in oncological patients
Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vásquez, Freddy Shanner Chávez-Vásquez, Alexandra Noelia Rodríguez-Angulo, Sonia Elizabeth Gonzáles-Saldaña, Carlos César Alcalde-Loyola, Julia Cristina Coronado-Arroyo, Francisca Elena Zavaleta-Gutiérre
Expert Review of Anticancer Therapy.2024; 24(1-2): 5. CrossRef Ifosfamide - History, efficacy, toxicity and encephalopathy
Jeffrey R. Idle, Diren Beyoğlu
Pharmacology & Therapeutics.2023; 243: 108366. CrossRef Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis
Obeid M. Malekshah, Siddik Sarkar, Alireza Nomani, Niket Patel, Parisa Javidian, Michael Goedken, Marianne Polunas, Pedro Louro, Arash Hatefi
Journal of Controlled Release.2019; 311-312: 273. CrossRef MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2
Shufeng Duan, Xuecai Dong, Jing Hai, Jinghong Jiang, Wenxiang Wang, Jing Yang, Wei Zhang, Caixia Chen
Biomedicine & Pharmacotherapy.2018; 107: 712. CrossRef
|